Bank of Montreal Can Grows Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Bank of Montreal Can grew its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 15.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,127 shares of the company’s stock after purchasing an additional 937 shares during the period. Bank of Montreal Can’s holdings in Prestige Consumer Healthcare were worth $557,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. MML Investors Services LLC boosted its holdings in Prestige Consumer Healthcare by 16.5% in the third quarter. MML Investors Services LLC now owns 4,328 shares of the company’s stock worth $312,000 after acquiring an additional 612 shares in the last quarter. Barclays PLC grew its position in Prestige Consumer Healthcare by 346.3% during the 3rd quarter. Barclays PLC now owns 92,444 shares of the company’s stock worth $6,665,000 after purchasing an additional 71,730 shares during the last quarter. Franklin Resources Inc. increased its stake in Prestige Consumer Healthcare by 4.3% during the 3rd quarter. Franklin Resources Inc. now owns 21,585 shares of the company’s stock valued at $1,513,000 after purchasing an additional 894 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Prestige Consumer Healthcare by 3.2% during the third quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock worth $19,630,000 after buying an additional 8,533 shares during the period. Finally, GAMMA Investing LLC grew its holdings in shares of Prestige Consumer Healthcare by 18.9% during the fourth quarter. GAMMA Investing LLC now owns 1,383 shares of the company’s stock valued at $108,000 after buying an additional 220 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Insider Activity at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 1,678 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the completion of the sale, the senior vice president now directly owns 17,157 shares in the company, valued at approximately $1,544,130. This trade represents a 8.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Trading Down 2.1 %

Shares of PBH stock opened at $78.62 on Tuesday. Prestige Consumer Healthcare Inc. has a fifty-two week low of $62.35 and a fifty-two week high of $90.04. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. The stock’s fifty day moving average is $84.04 and its two-hundred day moving average is $80.31. The firm has a market capitalization of $3.89 billion, a P/E ratio of 18.41, a PEG ratio of 2.69 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

PBH has been the topic of several research analyst reports. Royal Bank of Canada boosted their price target on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a “sector perform” rating in a research note on Friday, March 21st. StockNews.com cut shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research note on Tuesday, April 8th. Canaccord Genuity Group increased their price objective on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Oppenheimer upped their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a report on Thursday, February 13th. Finally, DA Davidson boosted their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a report on Friday, February 7th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Hold” and a consensus price target of $93.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.